KMDA Kamada Ltd.

-0.04  -1%
Previous Close 5.45
Open 5.44
Price To Book 1.85
Market Cap 217,996,372
Shares 40,295,078
Volume 18,552
Short Ratio
Av. Daily Volume 96,805

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due YE 2019.
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
Prophylaxis of rabies disease
Phase 3 trial planned for 2H 2019.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2 data released November 3, 2017. No significant treatment effect noted overall.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2 interim data due YE 2019.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)